Search results
Results from the WOW.Com Content Network
A recall has been ordered for a high-profile diabetes drug after producers discovered it contained alarmingly high levels of a cancer-causing impurity. Marksans Pharma Limited has recalled ...
A new cell study has shown the common type 2 diabetes medication metformin alters levels of microRNAs that target genes to slow down the growth and multiplication of colorectal cancer cells. The ...
Cancer pharmacogenomics is the study of how variances in the genome influences an individual’s response to different cancer drug treatments. It is a subset of the broader field of pharmacogenomics , which is the area of study aimed at understanding how genetic variants influence drug efficacy and toxicity.
Metformin inhibits cyclic AMP production, blocking the action of glucagon, and thereby reducing fasting glucose levels. [117] Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice, and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion. [108]
For premium support please call: 800-290-4726 more ways to reach us
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
The result of her experience has been a long-term passion for making sure women can advocate for themselves with their doctors—and do it early. “The reason why we lose loved ones to cancer ...